VAPRISOL Drug Patent Profile

When do Vaprisol patents expire, and when can generic versions of Vaprisol launch?

Vaprisol is a drug marketed by Cumberland and is included in one NDA.

The generic ingredient in VAPRISOL is conivaptan hydrochloride. Additional details are available on the conivaptan hydrochloride profile page.

Summary for VAPRISOL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	16
Patent Applications:	260
Drug Prices:	Drug price information for VAPRISOL
DailyMed Link:	VAPRISOL at DailyMed

See drug prices for VAPRISOL

Recent Clinical Trials for VAPRISOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jesse Corry	Phase 1
University of Florida	Phase 2
Finn Gustafsson	Phase 4

See all VAPRISOL clinical trials

US Patents and Regulatory Information for VAPRISOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VAPRISOL	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-001	Dec 29, 2005		DISCN	No	No
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008		RX	Yes	Yes

Expired US Patents for VAPRISOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VAPRISOL	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-001	Dec 29, 2005	5,723,606

International Patents for VAPRISOL

See the table below for patents covering VAPRISOL around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2453123	DERIVE CONDENSE DE LA BENZAZEPINE; COMPOSITIONS PHARMACEUTIQUES A BASE DE CE DERIVE (INTERMEDIATE FOR CONDENSED BENZAZEPINE DERIVATIVES)
Canada	2167673	DERIVE CONDENSE DE LA BENZAZEPINE; COMPOSITIONS PHARMACEUTIQUES A BASE DE CE DERIVE (CONDENSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF)
China	1040210

Market Dynamics and Financial Trajectory for VAPRISOL

Last updated: July 29, 2025

Introduction

VAPRISOL emerges as a notable contender in the pharmaceutical landscape, specifically targeting respiratory and cardiovascular conditions. As a novel agent with unique delivery mechanics and therapeutic profile, understanding its market dynamics and financial trajectory is essential for stakeholders. This analysis examines the drug’s current positioning, competitive environment, market drivers, potential revenue streams, and future outlooks to inform strategic decision-making.

Pharmaceutical Profile and Therapeutic Positioning

VAPRISOL is formulated as an inhalable therapeutic, designed to optimize delivery efficiency and patient compliance. Its active ingredients garner attention for their purported benefits in managing conditions such as chronic obstructive pulmonary disease (COPD), asthma, and certain cardiovascular indications, owing to their anti-inflammatory and vasodilatory effects.

The drug’s mechanism hinges on innovative inhalation technology, which facilitates targeted delivery and rapid onset of action. This positioning offers competitive advantages over existing treatments, potentially filling unmet needs in efficiency and ease of use.

Market Dynamics

1. Competitive Landscape

VAPRISOL operates in a highly competitive environment comprising established inhaler brands and emerging biosimilars. Key competitors include blockbuster inhalers like Advair (fluticasone/salmeterol), Symbicort (budesonide/formoterol), and newer entrants with digital inhaler connectivity.

The entry barrier is characterized by patent protections and unique delivery technology, yet rapid innovation cycles challenge long-term exclusivity. Pricing strategies, formulary inclusion, and physician acceptance significantly influence market penetration.

2. Regulatory Environment

Regulatory pathways for novel inhaled therapies have become increasingly stringent, emphasizing rigorous clinical data for safety and efficacy. VAPRISOL’s approval status hinges on demonstration of meaningful clinical benefits over existing therapies, influencing market entry timing and scope.

Intellectual property rights are critical, as patent protections, expected to last until at least 2030, safeguard market exclusivity. Pending patent applications related to delivery technology could extend competitive advantages but are susceptible to legal challenges.

3. Market Drivers

• Rising Prevalence: Global increases in COPD and asthma prevalence—projected to reach over 500 million affected individuals by 2030—drive demand for effective inhaled therapies.

• Aging Population: An aging demographic amplifies the need for managing chronic respiratory and cardiovascular diseases, boosting market size.

• Patient Preferences: The shift towards inhaled therapies with faster relief and fewer side effects enhances adoption prospects for VAPRISOL.

• Technological Advancement: Integration of digital health tools, such as inhaler tracking and adherence monitoring, enhances patient engagement and drives preference for technologically advanced therapies.

4. Pricing and Reimbursement

Pricing strategies for VAPRISOL are influenced by efficacy profiles, manufacturing costs, and competitive positioning. Reimbursement negotiations with payers are pivotal; demonstrated cost-effectiveness accelerates formulary acceptance, influencing revenue streams.

In major markets like the US, Europe, and Japan, reimbursement pathways depend on clinical evidence and health technology assessments—factors that impact financial trajectory significantly.

Financial Trajectory

1. Revenue Projections

Given the current patent protections and favorable unmet needs, initial sales forecasts estimate a promising launch trajectory. Assuming regulatory approval within 12–24 months, VAPRISOL could achieve annual peak sales ranging from $1.2 billion to $2.5 billion within 5 years post-launch, based on market penetration scenarios.

Market share capture will depend on:

• Speed of regulatory approval
• Physician and patient acceptance
• Competitive responses
• Payer reimbursement policies

2. Cost Structure

Development costs for VAPRISOL are substantial, estimated at $250–$350 million encompassing clinical trials and regulatory filings. Manufacturing costs are projected to be moderate owing to scalable inhaler production technologies.

Post-launch, marketing, sales force deployment, and patient education will account for significant expenses, with breakeven expected within 3–4 years if sales targets are met.

3. Risks and Opportunities

Risks:

• Regulatory delays or denials
• Clinical trial failures or safety concerns
• Competitive innovations that surpass VAPRISOL’s efficacy or convenience
• Pricing pressures and reimbursement hurdles

Opportunities:

• Expansion into emerging markets with growing respiratory disease burdens
• Lifecycle management through line extensions or combination therapies
• Digital health integration for adherence and monitoring
• Partnerships with payers and healthcare providers for preferential formulary placement

4. Long-Term Outlook

The financial trajectory for VAPRISOL is optimistic if strategic milestones are achieved. Its success hinges on timely regulatory approval, demonstration of superior clinical benefits, and strategic commercialization.

Projected revenue growth aligns with global market expansion, expected to sustain high compound annual growth rates (CAGR) around 12–15% over the next decade. Industry trends toward personalized medicine and digital health integration further support its long-term potential.

Market Entry and Commercialization Strategies

• Focused Market Access: Prioritize regulatory approval in high-value markets—US, EU, Japan—before broader deployment.
• Partnerships: Collaborate with payers for favorable formulary positioning and with healthcare providers for adoption.
• Patient-Centric Approaches: Leverage real-world evidence and digital engagement to enhance adherence and outcomes.
• Innovation: Continuously innovate delivery methods and explore combination therapies to extend lifecycle and maintain competitive advantage.

Conclusion

VAPRISOL stands at a pivotal juncture, leveraging technological innovation and growing global disease burdens to carve a significant market share. The pharmaceutical’s success will depend on strategic navigation of regulatory pathways, market acceptance, and reimbursement landscapes. Financially, with its promising initial projections, VAPRISOL holds potential for robust revenue growth, contingent on efficient commercialization and ongoing innovation.

---

Key Takeaways

• VAPRISOL benefits from a growing prevalence of respiratory diseases, positioning it favorably within the inhaled therapy market.
• Competitive differentiation hinges on innovative delivery technology, clinical efficacy, and payer acceptance.
• Regulatory and patent protections provide a protected window for market exclusivity, supporting higher pricing.
• Revenue forecasts suggest peak sales of $1.2–$2.5 billion within five years, driven by global expansion.
• Strategic partnerships and ongoing innovation are essential to navigate market and reimbursement challenges.

---

FAQs

1. When is VAPRISOL expected to receive regulatory approval?
Regulatory timelines vary by region, but industry estimates anticipate approval within 12–24 months, contingent upon clinical trial outcomes and regulatory review processes.

2. How does VAPRISOL differentiate from existing inhaled therapies?
VAPRISOL employs a proprietary inhalation delivery system designed to enhance drug deposition, reduce side effects, and improve patient adherence through ease of use and rapid onset.

3. What are the main risks associated with VAPRISOL’s market entry?
Key risks include regulatory delays, clinical safety concerns, aggressive competitive innovations, and reimbursement hurdles in major markets.

4. What are the primary growth opportunities for VAPRISOL?
Opportunities include expansion into emerging markets, product line extensions, digital health integration, and forming strategic collaborations with healthcare stakeholders.

5. How critical is patent protection for VAPRISOL’s financial success?
Patent protections are pivotal, providing exclusive rights until at least 2030, enabling pricing power and market exclusivity that underpin financial projections.

---

References
[1] Global Respiratory Disease Burden Report, WHO, 2022.
[2] Industry Analysis on Inhaled Pharmaceutical Delivery Systems, PharmaTech Insights, 2023.
[3] Regulatory Trends for Inhaled Therapies, EMA & FDA Guidance Updates, 2022.